158
Views
20
CrossRef citations to date
0
Altmetric
Review

Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins

Pages S29-S36 | Published online: 24 Nov 2005

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Percy H Carter & Qihong Zhao. (2010) Clinically validated approaches to the treatment of autoimmune diseases. Expert Opinion on Investigational Drugs 19:2, pages 195-213.
Read now
Klaus Bendtzen, Mark Ainsworth, Casper Steenholdt, Ole Østergaard Thomsen & Jørn Brynskov. (2009) Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scandinavian Journal of Gastroenterology 44:7, pages 774-781.
Read now
Roy Jefferis. (2007) Antibody therapeutics:. Expert Opinion on Biological Therapy 7:9, pages 1401-1413.
Read now

Articles from other publishers (17)

Pallawi Torka, Mathew Barth, Robert Ferdman & Francisco J. Hernandez-Ilizaliturri. (2019) Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies. Current Hematologic Malignancy Reports 14:5, pages 426-438.
Crossref
Shan Liu, Bo Xie, Wei Wei, Mizhou Hui & Zhiguo Su. (2016) Design and preparation of chimeric hyaluronidase as a chaperone for the subcutaneous administration of biopharmaceuticals. Biochemical Engineering Journal 112, pages 32-41.
Crossref
C. Dannepond, D. Ternant, A. Maruani, L. Machet, G. Paintaud & M. Samimi. (2015) Serum infliximab concentrations and disease activity: a descriptive study of patients with psoriasis. British Journal of Dermatology 174:1, pages 198-200.
Crossref
Emanual Maverakis, Kyoungmi Kim, Michiko Shimoda, M. Eric Gershwin, Forum Patel, Reason Wilken, Siba Raychaudhuri, L. Renee Ruhaak & Carlito B. Lebrilla. (2015) Glycans in the immune system and The Altered Glycan Theory of Autoimmunity: A critical review. Journal of Autoimmunity 57, pages 1-13.
Crossref
F. Bibeau & F. Boissi?re-Michot. (2014) Ph?nom?ne d?ADCC, polymorphismes du r?cepteur Fc? et cons?quences en termes de d?veloppement th?rapeutique cibl?The Phenomenon of Antibody Dependent Cell Cytotoxicity (ADCC), Polymorphism of the Fc? Receptor and Consequences in Terms of the Development of Targeted Therapy. Oncologie 16:2-3, pages 112-119.
Crossref
K. Bouzid, N. Bedairia & M. Marty. (2012) Anticorps monoclonaux thérapeutiques en cancérologie. Pathologie Biologie 60:4, pages 223-228.
Crossref
Klaus Bendtzen & Morten Svenson. 2011. Detection and Quantification of Antibodies to Biopharmaceuticals. Detection and Quantification of Antibodies to Biopharmaceuticals 81 101 .
David Ternant, Emilie Hénin, Guillaume Cartron, Michel Tod, Gilles Paintaud & Pascal Girard. (2009) Development of a drug-disease simulation model for rituximab in follicular non-Hodgkin's lymphoma. British Journal of Clinical Pharmacology 68:4, pages 561-573.
Crossref
Roy Jefferis. (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nature Reviews Drug Discovery 8:3, pages 226-234.
Crossref
Anne S. De GrootLeonard MoiseJulie A. McMurryErik Wambre, Laurence Van Overtvelt, Philippe Moingeon, David W. Scott & William Martin. (2008) Activation of natural regulatory T cells by IgG Fc–derived peptide “Tregitopes”. Blood 112:8, pages 3303-3311.
Crossref
Klaus Bendtzen. 2008. Immunogenicity of Biopharmaceuticals. Immunogenicity of Biopharmaceuticals 189 203 .
Nicolas Congy-Jolivet, Alicia Probst, Hervé Watier & Gilles Thibault. (2007) Recombinant therapeutic monoclonal antibodies: Mechanisms of action in relation to structural and functional duality. Critical Reviews in Oncology/Hematology 64:3, pages 226-233.
Crossref
Guillaume Cartron, Hélène Blasco, Gilles Paintaud, Hervé Watier & Chantal Le Guellec. (2007) Pharmacokinetics of rituximab and its clinical use: Thought for the best use?. Critical Reviews in Oncology/Hematology 62:1, pages 43-52.
Crossref
Elana A. Maser, Renata Villela, Mark S. Silverberg & Gordon R. Greenberg. (2006) Association of Trough Serum Infliximab to Clinical Outcome After Scheduled Maintenance Treatment for Crohn’s Disease. Clinical Gastroenterology and Hepatology 4:10, pages 1248-1254.
Crossref
Jean Sibilia. (2006) Les bioth?rapies immunomodulatrices: Une r?volution th?rapeutique dans les maladies auto-immunes. Revue Francophone des Laboratoires 2006:384, pages 34-39.
Crossref
Xiaohong Qi. (2006) Stochastic Models for Prodrug Targeting. 1. Diffusion of the Efflux Drug. Molecular Pharmaceutics 3:2, pages 187-195.
Crossref
Jean Sibilia. (2006) Bioth?rapies: ?volution ou r?volution?. La Presse M?dicale 35:4, pages 637-640.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.